The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma

Timothy B. Lautz, Chunfa Jie, Sandra Clark, Jessica A. Naiditch, Nadereh Jafari, Yi Yong Qiu, Xin Zheng, Fei Chu, Mary Beth Madonna

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Histone deacetylase (HDAC) inhibitors, especially vorinostat, are currently under investigation as potential adjuncts in the treatment of neuroblastoma. The effect of vorinostat co-treatment on the development of resistance to other chemotherapeutic agents is unknown. In the present study, we treated two human neuroblastoma cell lines [SK-N-SH and SK-N-Be(2)C] with progressively increasing doses of doxorubicin under two conditions: with and without vorinsotat co-therapy. The resultant doxorubicin-resistant (DoxR) and vorinostat-treated doxorubicin resistant (DoxR-v) cells were equally resistant to doxorubicin despite significantly lower P-glycoprotein expression in the DoxR-v cells. Whole genome analysis was performed using the Ilumina Human HT-12 v4 Expression Beadchip to identify genes with differential expression unique to the DoxR-v cells. We uncovered a number of genes whose differential expression in the DoxR-v cells might contribute to their resistant phenotype, including hypoxia inducible factor-2. Finally, we used Gene Ontology to categorize the biological functions of the differentially expressed genes unique to the DoxR-v cells and found that genes involved in cellular metabolism were especially affected.

Original languageEnglish (US)
Article numbere40816
JournalPloS one
Issue number7
StatePublished - Jul 19 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General


Dive into the research topics of 'The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma'. Together they form a unique fingerprint.

Cite this